Aligos Therapeutics Reveals Positive Phase 2a HERALD Study Findings for ALG-055009 in MASH Treatment’
SOUTH SAN FRANCISCO, Calif. Sept. 19, 2024’ Aligos Therapeutics, Inc. (Nasdaq: ALGS), a pioneering clinical stage biopharmaceutical firm dedicated to advancing therapeutic outcomes for liver and viral diseases, has announced encouraging topline results from its Phase 2a HERALD study investigating ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist. The study focuses on patients diagnosed with metabolic-dysfunction associated steatohepatitis, commonly referred to as MASH, a condition exacerbated by increasing rates of obesity and metabolic syndrome in contemporary populations.
MASH represents a significant and growing public health challenge, characterized by the accumulation of fat in the liver due to metabolic dysfunction, resulting in inflammation and potential progression to liver cirrhosis and hepatocellular carcinoma. Current treatment options are limited, underscoring the critical need for innovative therapies which can effectively address this condition.
The HERALD study aimed to evaluate both the safety and efficacy of ALG-055009 in MASH subjects. The topline data revealed statistically significant improvements in key histological measures, including reductions in liver inflammation and fat content, alongside favorable safety profiles. Notably, patients treated with ALG-055009 exhibited a notable improvement in liver histology, demonstrating the compound’s potential to alter the disease trajectory and improve patient outcomes.
Dr. Lise G. Kallewaard, Chief Medical Officer at Aligos, emphasized the implications of these findings, stating, “Our Phase 2a results are promising as they indicate that ALG-055009 may represent a breakthrough in the management of MASH. We are excited about the potential this therapy has to provide patients with a much-needed option where few exist. The data supports our hypothesis regarding the role of THR-β agonists in regulating metabolism and mitigating liver damage.”
The results generated by the HERALD study contribute to the growing body of evidence surrounding the therapeutic use of THR-β agonists in metabolic disorders. This class of drugs is recognized for its ability to enhance metabolic processes and facilitate weight loss, thereby addressing both the symptoms and underlying causes of metabolic syndrome.
With the positive outcomes from the HERALD study, Aligos Therapeutics plans to further explore the mechanisms of ALG-055009 in larger, more extensive clinical trials, aiming to substantiate its efficacy across diverse populations suffering from MASH. The company is committed to collaborating with regulatory authorities to design robust study protocols that align with the urgent need for effective interventions in this patient population.
As a leading entity in biopharmaceutical innovation, Aligos Therapeutics continues to position itself at the forefront of medical advancements in the fight against liver diseases. The company remains dedicated to transforming the therapeutic landscape for MASH and improving the overall quality of life for affected individuals. The forthcoming research phases will aim not only at validating its current results but also at expanding treatment options for a condition that currently lacks sufficient therapeutic strategies.
As the clinical landscape evolves, the developments surrounding ALG-055009 could indeed redefine the potential management of metabolic dysfunction-associated steatohepatitis, illustrating the profound impact of targeted biopharmaceutical interventions in modern medicine.
Comments